XML 34 R52.htm IDEA: XBRL DOCUMENT v2.4.0.6
Collaborative Research, Development, and License Agreements - Additional Information (Detail) (USD $)
 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 1 Months Ended 12 Months Ended 3 Months Ended 1 Months Ended 1 Months Ended
Dec. 31, 2008
Glaxo, Smith, Kline
Project
Dec. 31, 2012
Glaxo, Smith, Kline
Dec. 31, 2011
Glaxo, Smith, Kline
Dec. 31, 2010
Glaxo, Smith, Kline
Sep. 30, 2006
Astra Zeneca
Dec. 31, 2012
Astra Zeneca
Dec. 31, 2011
Astra Zeneca
Dec. 31, 2010
Astra Zeneca
Dec. 31, 2008
Astra Zeneca
Oct. 31, 2011
Astra Zeneca
Amendment
Dec. 31, 2011
Astra Zeneca
Amendment
Dec. 31, 2012
Astra Zeneca
Amendment
Advance the program following completion of Phase 2a
Mar. 31, 2012
Astra Zeneca
Amendment
Advance the program following completion of Phase 2a
May 31, 2012
National Institutes of Health
Rheumatoid Arthiritis
Jun. 30, 2012
National Institutes of Health
Autoimmune Disease
Jul. 31, 2011
National Institutes of Health
Skin Autoimmune Inflammation
Aug. 31, 2010
National Institutes of Health
HBV
Jul. 31, 2010
National Institutes of Health
HPV
Sep. 30, 2008
National Institutes of Health
ISS Technology
Jul. 31, 2008
National Institutes of Health
SLE
Mar. 31, 2010
Merck
HBV
Product Information [Line Items]                                          
Number of programs for research and early clinical development 4                                        
Collaboration revenue $ 10,000,000 $ 1,428,000 $ 1,428,000 $ 1,428,000 $ 10,000,000 $ 720,000 $ 120,000 $ 10,778,000   $ 3,000,000   $ 6,000,000 $ 2,600,000               $ 4,000,000
Revenue from milestone payment     15,000,000     2,462,000 642,000 3,315,000 4,500,000     20,000,000                  
Deferred revenue recognition period   7 years       50 months                              
Deferred revenue   4,200,000 5,700,000     7,700,000 4,900,000                            
Research collaboration and license agreement period         3 years                                
Cost of clinical development activities                     20,000,000                    
Grants receivable                           400,000 600,000 600,000 1,100,000 600,000   1,800,000  
Contract agreement period                                     5 years    
Contract awarded to develop technology                                     $ 17,000,000